Alternate Name(s):
Keflex
Classification:
Cephalosporin Antibiotic
Original Date:
January 2009
Revised Date:
March 2022
Indications:
- Treatment of noninvasive infections due to susceptible organisms.
- Not recommended for invasive infections (e.g meningitis, bacteremia, osteomyelitis, abscesses, pneumonia)
- UTI prophylaxis in children with congenital antenatal hydronephrosis, high-grade vesicouretral reflux or ureterovesical junction obstruction
- Voiding Cystourethrogram (VCUG) prophylaxis (when not on prophylaxis for UTI)
Administration:
- PO: administer on an empty stomach, or with food if GI upset occurs
Dosage:
| Age | Dose |
| < 7 days |
50 mg/kg/day divided Q12H Dose limit: 250 mg/day |
| 7 - 21 days |
75 mg/kg/day divided Q8H Dose limit: 375 mg/day |
| > 21 days |
100 mg/kg/day divided Q6H Dose limit: 500 mg/day |
UTI prophylaxis:
- 15 mg/kg/day divided BID for neonates up to 6 weeks of age. May give total daily dose once daily beyond 6 weeks of age.
Voiding Cystourethrogram (VCUG) prophylaxis:(when not on prophylaxis for UTI)
- Administer dose within 60 minutes of voiding cystourethrogram (VCUG)
- > 35 weeks GA and < 2 weeks PNA: 25 mg/kg/dose PO x 1
- > 35 weeks GA and > 2 weeks PNA: 50 mg/kg/dose PO x 1
- > 35 weeks GA and > 4 weeks PNA: 75 mg/kg/dose PO x 1
Dosage adjustment required in renal impairment. Refer to available references or clinical pharmacist for dosage adjustment.
Side Effects:
- GI: nausea, vomiting, diarrhea
- Hematologic: transient neutropenia, thrombocytopenia, anemia
- Hepatic: transient elevation in liver enzymes
Parameters to Monitor:
- With prolonged therapy, monitor renal, hepatic and hematologic function periodically
Reconstitution and Stability:
N/A
Compatibility:
N/A